Salma K. Jabbour, MD, Discusses the Value of Treating Patients With NSCLC in a Multidisciplinary Setting


Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.

CancerNetwork® sat down with Salma K. Jabbour, MD, of the Rutgers Cancer Institute of New Jersey, to discuss how patients with stage III non–small cell lung cancer (NSCLC) treated on the phase 2 KEYNOTE-799 trial (NCT03631784) that was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting can benefit from a multidisciplinary approach to care.

In the trial, patients with unresectable, locally advanced NSCLC were treated with pembrolizumab plus platinum doublet chemotherapy and radiotherapy followed by pembrolizumab monotherapy.


It's really important for [patients with stage III NSCLC] to be evaluated in a multidisciplinary setting and to be managed in a multidisciplinary setting and it is very much a team approach from the onset of the patient's care. I think that really can't be underestimated because these patients require a lot of attention and care to make sure that their treatment really goes smoothly and [adverse] effects from chemoradiation can be managed, such as esophagitis, dermatitis, and pneumonitis. That is really an important component. The communication with the team, both from the medical oncologist, the radiation oncologist, and initial involvement from the surgeon make the determination about resectability. All of it is really important and helps to carry the patient through with a tolerable toxicity profile and…have them achieve a successful and manageable therapy.


Jabbour SK, Lee H, Frost N, et al. KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC. J Clin Oncol. 2021;39(suppl 15):8512. doi:10.1200/JCO.2021.39.15_suppl.8512.

Related Videos
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content